Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47914 | 0.88 | APLNR (0.50) | MTNR1AMTNR1BHSD17B10 | |
| SCHEMBL29279598 | 0.86 | ADRA1A (0.59) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL4708636 | 0.84 | MTNR1A (0.46) | MTNR1AMTNR1BHSD17B10 | |
| SCHEMBL13034128 | 0.84 | HSD17B10 (0.61) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL6583328 | 0.83 | ALDH1A1 (0.53) | MTNR1AMTNR1BHSD17B10 | |
| SCHEMBL11077966 | 0.81 | MTNR1A (0.62) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL27974256 | 0.80 | POLB (0.43) | MTNR1AMTNR1BIDO1HTR2A | |
| SCHEMBL20072234 | 0.79 | MTNR1A (0.59) | MTNR1AMTNR1BTAAR1AOC3 | |
| SCHEMBL7332981 | 0.79 | HSD17B10 (0.63) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL491188 | 0.78 | HSD17B10 (0.71) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-1614419-B1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-08-08 | — | — | EP | disclosed |
| CN-101643470-B | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO LTD | 2012-08-01 | — | — | CN | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8067406-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-7897594-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| CN-101643470-A | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO LTD JP | 2010-02-10 | — | — | CN | disclosed |
| CN-100500662-C | Alkyl ether derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2009-06-17 | — | — | CN | disclosed |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1614419-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| CN-1571786-A | Alkyl ether derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2005-01-26 | — | — | CN | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | RB1, ALDH1A2, NR2E3 | MTNR1A 73/4885MTNR1B 273/4885HSD17B10 1320/4885 |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | MTNR1A 73/4885MTNR1B 273/4885HSD17B10 1320/4885 |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | MTNR1A 3214/4885MTNR1B 3892/4885HSD17B10 2695/4885 |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | MTNR1A 73/4885MTNR1B 273/4885HSD17B10 1320/4885 |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | AHNAK, NGF, PMP22 | MTNR1A 3214/4885MTNR1B 3892/4885HSD17B10 2695/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | MTNR1A 3214/4885MTNR1B 3892/4885HSD17B10 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.